Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Inventory (2023 - 2025)

Tarsus Pharmaceuticals has reported Inventory over the past 3 years, most recently at $4.4 million for Q4 2025.

  • Quarterly results put Inventory at $4.4 million for Q4 2025, up 66.87% from a year ago — trailing twelve months through Dec 2025 was $4.4 million (up 66.87% YoY), and the annual figure for FY2025 was $4.4 million, up 66.87%.
  • Inventory for Q4 2025 was $4.4 million at Tarsus Pharmaceuticals, up from $3.8 million in the prior quarter.
  • Over the last five years, Inventory for TARS hit a ceiling of $4.4 million in Q4 2025 and a floor of $15000.0 in Q3 2023.
  • Median Inventory over the past 3 years was $3.0 million (2023), compared with a mean of $3.0 million.
  • Biggest five-year swings in Inventory: surged 18873.33% in 2024 and later tumbled 32.98% in 2025.
  • Tarsus Pharmaceuticals' Inventory stood at $3.1 million in 2023, then fell by 15.67% to $2.6 million in 2024, then soared by 66.87% to $4.4 million in 2025.
  • The last three reported values for Inventory were $4.4 million (Q4 2025), $3.8 million (Q3 2025), and $3.9 million (Q2 2025) per Business Quant data.